The prevalence of T2D among a cohort of patients in Italy with SSc was lower than national estimates and associated with distinct vascular and cardiopulmonary features.
The presentation places the EMERALD trial within the broader treatment context of metastatic ER+/HER2– disease. As resistance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback